# Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma

> **NCT05994365** · — · RECRUITING · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 380 (estimated)

## Conditions studied

- Thyroid Neoplasms

## Interventions

- **DRUG:** Anlotinib Hydrochloride Capsule

## Key facts

- **NCT ID:** NCT05994365
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08
- **Primary completion:** 2027-08
- **Final completion:** 2028-12
- **Target enrollment:** 380 (ESTIMATED)
- **Last updated:** 2023-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05994365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05994365, "Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT05994365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*